4//SEC Filing
Corcoran Gavin 4
Accession 0001209191-20-036804
CIK 0001636050other
Filed
Jun 14, 8:00 PM ET
Accepted
Jun 15, 7:38 PM ET
Size
9.5 KB
Accession
0001209191-20-036804
Insider Transaction Report
Form 4
Corcoran Gavin
EVP of R&D
Transactions
- Award
Common Shares
2020-06-12+16,002→ 16,002 total - Tax Payment
Common Shares
2020-06-12$3.46/sh−6,211$21,490→ 9,791 total - Disposition to Issuer
Restricted Stock Units
2020-06-12−16,002→ 16,001 total→ Common Shares (16,002 underlying)
Footnotes (3)
- [F1]The shares were sold on behalf of the Reporting Person in the open market to cover withholding taxes relating to the settlement of the vested restricted stock units.
- [F2]Each restricted stock unit represents the right to receive one share of the Issuer's common stock. 50% of the common shares underlying the restricted stock units vested on January 31, 2020 but settlement of such portion of the restricted stock units was delayed until transactions acceptable under the Issuer's insider trading policy were permitted
- [F3]50% of the common shares underlying the restricted stock units vest on January 31, 2020 and the remainder vest on July 31, 2020, subject to the Reporting Person providing continuous service to the Issuer through each such date.
Documents
Issuer
Axovant Gene Therapies Ltd.
CIK 0001636050
Entity typeother
Related Parties
1- filerCIK 0001745995
Filing Metadata
- Form type
- 4
- Filed
- Jun 14, 8:00 PM ET
- Accepted
- Jun 15, 7:38 PM ET
- Size
- 9.5 KB